To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Dr. Balasubramanian completed his medical training at Madras Medical College in India. His interest in treating malignant hematology patients grew with his advanced training in Singapore in the Department of Hematology and Bone Marrow Transplant. He was intrigued by the advancement of cancer genetics and its application in developing novel therapeutics. His inner calling for malignant hematology and leukemia research was further strengthened by the translational hematology research fellowship in bone marrow failures and myeloid neoplasms at Dr. Maciejewski's lab at Cleveland Clinic. Dr. Balasubramanian was part of CCF's MDS/AML research group's collaborative effort to perform and analyze comprehensive next-generation sequencing on a large cohort of myeloid neoplasm patients. After completing a hematology/oncology fellowship training at Wayne State University, he remains a faculty treating malignant hematology and bone marrow failure patients. He is a Clinical Scholar and feels privileged being a Physician-Scientist since it gives the insight and understanding to allow for applying basic science and preclinical research to actual patients.
Dr. Balasubramanian's research focuses on understanding the genetic basis of myeloid neoplasms and applying this knowledge to improve outcomes for patients with these disorders. His research has focused on studying the clonal architecture in MDS, MDS/MPN, AML, and clonal hematopoiesis of indeterminate potential. His lab is interested in the epigenetic regulators in myeloid neoplasms and is translating the generated preclinical results to the bedside for treating myeloid neoplasms. He is a hematologist/oncologist and has a clinical focus on malignant myeloid neoplasms and bone marrow failure conditions. He has various publications in malignant hematology and was awarded a talent merit award by ASCO in 2016 for outstanding research presentations. Besides this, he has also gotten the opportunity at ASH and ASCO for a few oral presentations of his research work.
Patient Power Suresh Balasubramanian, M.D. , hematologist and medical oncologist, and member of the Hematology Oncology and Multiple Myeloma and Amyloidosis Multidisciplinary Teams at Karmanos, explains similarities and differences between myeloproliferative neoplasms (MPNs) and leukemia. Read the article here .
The Molecular Therapeutics (MT) Research Program at the Barbara Ann Karmanos Cancer Institute honors two research members with the Top Paper Award: Suresh Balasubramanian, M.D. , member of the Hematology Oncology and Multiple Myeloma and Amyloidosis Multidisciplinary Teams at Karmanos, as well as assistant professor of oncology at Wayne State University’s (WSU) School of Medicine, and Guojun Wu, Ph.D., associate professor in basic science at WSU. Both were awarded during the 2023 Molecular Therapeutics ...